Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives

Journal of the American College of Cardiology

Volumn 71, Issue 15, 2018, Pages 1696-1706

  González, Arantxa ^a,b   Schelbert, Erik B ^c   Díez, Javier ^a,b,d   Butler, Javed ^e  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Carlos III Institute of Health ^*  (Spain)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

diagnosis; fibrosis; heart failure; mechanisms; myocardium; therapeutics

Indexed keywords

COLLAGEN; INTERSTITIAL COLLAGENASE; LISINOPRIL; LOSARTAN; MINERALOCORTICOID ANTAGONIST; PROCOLLAGEN TYPE 1 CARBOXYPROPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SACUBITRIL PLUS VALSARTAN; SPIRONOLACTONE; TORASEMIDE; UNCLASSIFIED DRUG; VALSARTAN; BIOLOGICAL MARKER;

CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; DISEASE ASSOCIATION; DRUG EFFECT; EXTRACELLULAR SPACE; FIBROGENESIS; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MYOFIBROBLAST; NON INVASIVE MEASUREMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; BLOOD; CARDIAC IMAGING; CARDIAC MUSCLE; FIBROSIS; HEART; PATHOLOGY;

BIOMARKERS; CARDIAC IMAGING TECHNIQUES; FIBROSIS; HEART; HEART FAILURE; HUMANS; MYOCARDIUM;

EID: 85044595745     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.02.021     Document Type: Review

References (63)

1. Weber, K.T., Pick, R., Jalil, J.E., Janicki, J.S., Carroll, E.P., Patterns of myocardial fibrosis. J Mol Cell Cardiol 21 Suppl 5 (1989), 121–131.
2. Weber, K.T., Sun, Y., Guarda, E., Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 23;6 Pt 2 (1994), 869–877.
3. Beltrami, C.A., Finato, N., Rocco, M., et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89 (1994), 151–163.
4. Hoyt, R.H., Ericksen, E., Collins, S.M., Skorton, D.J., Computer-assisted quantitation of myocardial fibrosis in histologic sections. Arch Pathol Lab Med 108 (1984), 280–283.
5. Treibel, T.A., López, B., González, A., et al. Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur Heart J 39 (2018), 699–709.
6. López, B., González, A., Querejeta, R., Larman, M., Rábago, G., Díez, J., Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension 63 (2014), 483–489.
7. Echegaray, K., Andreu, I., Lazkano, A., et al. Role of myocardial collagen in severe aortic stenosis with preserved ejection fraction and symptoms of heart failure. Rev Esp Cardiol (English ed) 70 (2017), 832–840.
8. Mukherjee, D., Sen, S., Alteration of collagen phenotypes in ischemic cardiomyopathy. J Clin Invest 88 (1991), 1141–1146.
9. Shoulders, M.D., Raines, R.T., Collagen structure and stability. Annu Rev Biochem 78 (2009), 929–958.
10. Kasner, M., Westermann, D., López, B., et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol 57 (2011), 977–985.
11. López, B., Querejeta, R., González, A., et al. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension 60 (2012), 677–683.
12. Zile, M.R., Baicu, C.F., Ikonomidis, J., et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 131 (2015), 1247–1259.
13. Kong, P., Christia, P., Frangogiannis, N.G., The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 71 (2014), 549–574.
14. Weber, K.T., Sun, Y., Bhattacharya, S.K., Ahokas, R.A., Gerling, I.C., Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 10 (2013), 15–26.
15. Piccoli, M.T., Bär, C., Thum, T., Non-coding RNAs as modulators of the cardiac fibroblast phenotype. J Mol Cell Cardiol 92 (2016), 75–81.
16. Bomb, R., Heckle, M.R., Sun, Y., et al. Myofibroblast secretome and its auto-paracrine signaling. Expert Rev Cardiovasc Ther 14 (2016), 591–598.
17. Bishop, J.E., Laurent, G.J., Collagen turnover and its regulation in the normal and hypertrophying heart. Eur Heart J 16 Suppl C (1995), 38–44.
18. Trackman, P.C., Lysyl oxidase isoforms and potential therapeutic opportunities for fibrosis and cancer. Expert Opin Ther Targets 20 (2016), 935–945.
19. van der Slot-Verhoven, A.J., van Dura, E.A., Attema, J., et al. The type of collagen cross-link determines the reversibility of experimental skin fibrosis. Biochim Biophys Acta 1740 (2005), 60–67.
20. Aoki, T., Fukumoto, Y., Sugimura, K., et al. Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. Comparison between preserved and reduced ejection fraction heart failure. Circ J 75 (2011), 2605–2613.
21. Villari, B., Campbell, S.E., Hess, O.M., et al. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol 22 (1993), 1477–1484.
22. Nguyen, M.N., Kiriazis, H., Gao, X.M., Du, X.J., Cardiac fibrosis and arrhythmogenesis. Compr Physiol 7 (2017), 1009–1049.
23. McLenachan, J.M., Dargie, H.J., Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 3 (1990), 735–740.
24. Sabbah, H.N., Sharov, V.G., Lesch, M., Goldstein, S., Progression of heart failure: a role for interstitial fibrosis. Mol Cell Biochem 147 (1995), 29–34.
25. Dai, Z., Aoki, T., Fukumoto, Y., Shimokawa, H., Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure. J Cardiol 60 (2012), 416–421.
26. Azevedo, C.F., Nigri, M., Higuchi, M.L., et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 56 (2010), 278–287.
27. Yamada, T., Fukunami, M., Ohmori, M., et al. Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint. J Am Coll Cardiol 21 (1993), 628–633.
28. López, B., Ravassa, S., González, A., et al. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol 67 (2016), 251–260.
29. Ravassa, S., López, B., Querejeta, R., et al. Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. J Hypertens 35 (2017), 853–861.
30. López, B., González, A., Ravassa, S., et al. Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol 65 (2015), 2449–2456.
31. Prockop, D.J., Kivirikko, K.I., Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 64 (1995), 403–434.
32. Querejeta, R., López, B., González, A., et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110 (2004), 1263–1268.
33. López, B., Querejeta, R., González, A., Sánchez, E., Larman, M., Díez, J., Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 43 (2004), 2028–2035.
34. Izawa, H., Murohara, T., Nagata, K., et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112 (2005), 2940–2945.
35. Löfsjögård, J., Kahan, T., Díez, J., et al. Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. J Cardiovasc Med (Hagerstown) 15 (2014), 463–469.
36. Krum, H., Elsik, M., Schneider, H.G., et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail 4 (2011), 561–568.
37. Löfsjögård, J., Kahan, T., Díez, J., et al. Usefulness of collagen carboxy-terminal propeptide and telopeptide to predict disturbances of long-term mortality in patients ≥60 years with heart failure and reduced ejection fraction. Am J Cardiol 119 (2017), 2042–2048.
38. Flevari, P., Theodorakis, G., Leftheriotis, D., et al. Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure. Am Heart J 164 (2012), 530–537.
39. Klappacher, G., Franzen, P., Haab, D., et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75 (1995), 913–918.
40. Zannad, F., Alla, F., Dousset, B., Perez, A., Pitt, B., Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102 (2000), 2700–2706.
41. Gulati, A., Jabbour, A., Ismail, T.F., et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309 (2013), 896–908.
42. Schelbert, E.B., Sabbah, H.N., Butler, J., Gheorghiade, M., Employing extracellular volume cardiovascular magnetic resonance measures of myocardial fibrosis to foster novel therapeutics. Circ Cardiovasc Imaging, 10, 2017, e005619.
43. Chin, C.W., Everett, R.J., Kwiecinski, J., et al. Myocardial fibrosis and cardiac decompensation in aortic stenosis. J Am Coll Cardiol Img 10 (2017), 1320–1333.
44. Schelbert, E.B., Piehler, K.M., Zareba, K.M., et al. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. J Am Heart Assoc, 4, 2015, e002613.
45. Diao, K., Yang, Z., Xu, H., et al. Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis. J Cardiovasc Magn Reson, 18, 2016, 92.
46. Miller, C.A., Naish, J., Bishop, P., et al. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging 6 (2013), 373–383.
47. Fontana, M., White, S.K., Banypersad, S.M., et al. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson, 14, 2012, 88.
48. Schelbert, E.B., Testa, S.M., Meier, C.G., et al. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. J Cardiovasc Magn Reson, 13, 2011, 16.
49. Chin, C.W., Semple, S., Malley, T., et al. Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging 15 (2014), 556–565.
50. Singh, A., Horsfield, M.A., Bekele, S., Khan, J., Greiser, A., McCann, G.P., Myocardial T1 and extracellular volume fraction measurement in asymptomatic patients with aortic stenosis: reproducibility and comparison with age-matched controls. Eur Heart J Cardiovasc Imaging 16 (2015), 763–770.
51. Schelbert, E.B., Fridman, Y., Wong, T.C., et al. Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome JAMA. Cardiol 2 (2017), 1–12.
52. Treibel, T.A., Fontana, M., Steeden, J.A., et al. Automatic quantification of the myocardial extracellular volume by cardiac computed tomography: synthetic ECV by CCT. J Cardiovasc Comput Tomogr 11 (2017), 221–226.
53. Puntmann, V.O., Carr-White, G., Jabbour, A., et al. T1-mapping and outcome in nonischemic cardiomyopathy: All-cause mortality and heart failure. J Am Coll Cardiol Img 9 (2016), 40–50.
54. Brilla, C.G., Funck, R.C., Rupp, H., Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102 (2000), 1388–1393.
55. Díez, J., Querejeta, R., López, B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 (2002), 2512–2517.
56. López, B., Querejeta, R., González, A., Beaumont, J., Larman, M., Díez, J., Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 53 (2009), 236–242.
57. Gourdie, R.G., Dimmeler, S., Kohl, P., Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease. Nat Rev Drug Discov 15 (2016), 620–638.
58. Roubille, F., Busseuil, D., Merlet, N., Kritikou, E.A., Rhéaume, E., Tardif, J.C., Investigational drugs targeting cardiac fibrosis. Expert Rev Cardiovasc Ther 12 (2014), 111–125.
59. Gyöngyösi, M., Winkler, J., Ramos, I., et al. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail 19 (2017), 177–191.
60. Heydari, B., Abdullah, S., Pottala, J.V., et al. Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL randomized clinical trial. Circulation 134 (2016), 378–391.
61. Treibel, T.A., Kozor, R., Schofield, R., et al. Reverse myocardial remodeling in aortic stenosis: Cellular hypertrophy and extracellular volume but not focal fibrosis regress following aortic valve replacement. J Am Coll Cardiol 71 (2018), 860–871.
62. Zannad, F., Radauceanu, A., Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail Rev 10 (2005), 71–78.
63. Zile, M.R., Jhund, P.S., Baicu, C.F., et al., for the Prospective Comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) Investigators. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction study. Circ Heart Fail, 9, 2016, e002551.